Journey Medical (Journey Medical) FCF Margin % : -108.28% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Journey Medical FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Journey Medical's Free Cash Flow for the three months ended in Dec. 2023 was $-16.52 Mil. Journey Medical's Revenue for the three months ended in Dec. 2023 was $15.26 Mil. Therefore, Journey Medical's FCF Margin % for the quarter that ended in Dec. 2023 was -108.28%.

As of today, Journey Medical's current FCF Yield % is 0.34%.

The historical rank and industry rank for Journey Medical's FCF Margin % or its related term are showing as below:

DERM' s FCF Margin % Range Over the Past 10 Years
Min: -45.52 Med: 0.3 Max: 18.95
Current: 0.3

During the past 5 years, the highest FCF Margin % of Journey Medical was 18.95%. The lowest was -45.52%. And the median was 0.30%.

DERM's FCF Margin % is ranked better than
52.63% of 1026 companies
in the Drug Manufacturers industry
Industry Median: -0.675 vs DERM: 0.30

Journey Medical FCF Margin % Historical Data

The historical data trend for Journey Medical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Journey Medical FCF Margin % Chart

Journey Medical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

18.95

8.83

-19.29

-45.52

0.30

Journey Medical Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial											-24.03	-48.77	23.11	54.28	-108.28

Competitive Comparison of Journey Medical's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Journey Medical's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Journey Medical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Journey Medical's FCF Margin % falls into.

Journey Medical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Journey Medical's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	0.24	/	79.181
	=	0.30 %

Journey Medical's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-16.52	/	15.257
	=	-108.28 %

Journey Medical FCF Margin % Related Terms

Thank you for viewing the detailed overview of Journey Medical's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Journey Medical (Journey Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Journey Medical Corp (NAS:DERM) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258

Website

https://www.journeymedicalcorp.com

Journey Medical Corp is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm, etc.

Executives

Jeffrey Paley	director	C/O RETROPHIN INC., 777 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10017
Justin Adam Smith	director	C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
Claude Maraoui	director, officer: President & CEO	C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Joseph Benesch	officer: Interim CFO	C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
De Paolantonio Ernest Robert	officer: Chief Financial Officer	4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135